Fig. 6.

Palbociclib mediated GMB suppression is associated with an increased in miR-627-5p. a Western blots of TMZ-R cells without (−) and with (+) the treatment of palbociclib. Post palbociclib treatment, the expression of CDK6, EGFR, Sox2 and β-catenin was prominently lower as compared to their un-treated counterparts. b Predicted binding sites of miR-627-5p’s targets. Different algorithms were used to predict the potential targets for miR-627-5p such as CDK6, CTNNB1 and Sox2. c Real-time PCR analysis showed that inhibitor of miR-627-5p transfection led to increased level of CDK6, Sox2, CTNNB1 and lncSNHG15 while the opposite was observed in TMZ-R cells transfected with miR-627-5p mimic. **P < 0.01; ***P < 0.005. d TMZ sensitivity was associated with the level of miR-627-5p. TMZ-R cells with exogenous miR-627-5p (mimic) became more sensitive (approximately 200 μM, 48 h) towards TMZ as compared to the NC (approximately 300 μM, 48 h) whereas decreased miR-627-5p by inhibitor led to a significantly increased resistance against TMZ (IC50 > 500 μM, 48 h). e Negative correlation between CDK6 and miR-627-5p level in TMZ-resistant clinical samples